Preclinical Models & Translational Research

(P 170) ANTITUMOR ACTIVITY OF TAZEMETOSTAT AND DOXORUBICIN COMBINATION ON PATIENT-DERIVED PRECLINICAL MODELS OF EPITHELIOID SARCOMA

(P 171) CANINE-DERIVED OSTEOSARCOMA ORGANOIDS MODEL TUMOR HETEROGENEITY AND CHEMOTHERAPY RESISTANCE

(P 172) DEVELOPMENT OF A TARGETED DUAL-MODALITY RADIOIMMUNOCONJUGATE FOR IMAGE GUIDED SARCOMA SURGERY

(P 173) DYSREGULATION OF MITOCHONDRIAL DYNAMICS IN WELL-DIFFERENTIATED/DEDIFFERENTIATED LIPOSARCOMA PROVIDES A UNIQUE SUSCEPTABILITY TO NOVEL THERAPY

(P 174) ESTABLISHMENT AND CHARACTERIZATION OF A PATIENT-DERIVED SOLITARY FIBROUS TUMOR/HEMANGIOPERICYTOMA CELL LINE MODEL

(P 175) FIBRIN-ALGINATE INTERPENETRATING NETWORK HYDROGELS AS BIOMIMETIC PLATFORMS TO STUDY OSTEOSARCOMA

(P 176) FIBROBLAST ACTIVATION PROTEIN ALPHA AS THERANOSTIC TARGET IN SARCOMA

(P 177) GENOMIC LANDSCAPE OF RARE EWSR1 FUSIONS

(P 178) HIGH FREQUENCY OF NAPRT-SILENCING IN NEUROBLASTOMA AND RHABDOMYSARCOMA CONFERS SENSITIVITY TO TARGETING OF NAD+ METABOLISM USING NAMPT INHIBITORS

(P 179) IMMUNOSUPPRESSIVE MYELOID CELLS ARE INCREASED IN PATIENTS WITH SOFT TISSUE SARCOMA (STS) AND ARE NEGATIVELY ASSOCIATED WITH SURVIVAL

(P 180) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES

(P 181) MITOCHONDRIAL TRANSFER FROM MESENCHYMAL STEM CELSS MEDIATED BY HMGB1 COULD BE INVOLVED IN DRUG RESISTANCE IN OSTEOSARCOMA CELLS.

(P 182) NOVEL TISSUE MICROARRAY (TMA) PLATFORM AS A TOOL FOR COLLABORATIVE SOFT TISSUE SARCOMA (STS) RESEARCH

(P 183) OSTEOSARCOMA ORGANOIDS RECAPITULATE TUMOR CHARACTERISTICS AND MAINTAIN HETEROGENEITY

(P 184) PAN-SARCOMA ORGANOID SCREENING PIPELINE

(P 185) PHARMACOLOGICAL INHIBITION OF GLYOXALASE-1 AS NOVEL THERAPEUTIC STRATEGY TO POTENTIATE TRABECTEDIN ANTI-TUMOR EFFECT IN SOFT TISSUE SARCOMA PRECLINICAL MODELS

(P 186) PRECLINICAL STUDY OF DOXORUBICIN IN COMBINATION WITH PANOBINOSTAT IN XENOGRAFT MICE MODELS OF SOFT TISSUE SARCOMAS

(P 187) PRECLINICAL VALIDATION OF TARGET ENGAGEMENT ASSAYS AND INVESTIGATION OF MECHANISTIC IMPACTS OF FHD-609, A CLINICAL-STAGE BRD9 DEGRADER BEING DEVELOPED FOR THE TREATMENT OF SYNOVIAL SARCOMA

(P 188) PRELIMINARY ASSESSMENT OF CIRCULATING INFLAMMATORY CYTOKINES IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE) PATIENTS AND IN AN EHE PATIENT-DERIVED XENOGRAFT BEFORE AND AFTER DOXORUBICIN AND SIROLIMUS

(P 189) PROGNOSTIC IMPACT OF NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA-1 EXPRESSION AND HUMAN LEUKOCYTE ANTIGEN SUBTYPES IN METASTATIC SYNOVIAL SARCOMA

(P 190) SELECTIVELY TARGETING THE EPIGENOME IN EMBRYONAL RHABDOMYOSARCOMA

(P 191) SYNERGISTIC ACTIVITY OF PARP INHIBITORS IN COMBINATION WITH STANDARD CHEMOTHERAPY IN LEIOMYOSARCOMA

(P 192) TARGETING PI3K/MTOR MITIGATES RESISTANCE TO CDK4/6 INHIBITION IN RB-PROFICIENT PEDIATRIC AND AYA OSTEOSARCOMAS

(P 193) TARGETING THE PAX-FOXO FUSION VIA HDAC INHIBITION IN RHABDOMYOSARCOMA

(P 194) THE EHE BIOBANK: PATIENTS POWERING RARE CANCER MODEL DEVELOPMENT & TRANSLATIONAL RESEARCH

(P 195) THE STRATEGIC ROLE OF 3D CULTURE SYSTEMS AND ZEBRAFISH NEAR-PATIENTS PRECLINICAL PLATFORMS AS PREDICTIVE TOOLS OF CHEMOTHERAPY RESPONSE FOR SARCOMA

(P 197) TUMOR IMMNUNE PROFILING AND IDENTIFICATION OF IMMUNOTHERAPEUTIC TARGETS IN DEDIFFERENTIATED LIPOSARCOMA

(P 198) XENOSARC: A PANEL OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF SOFT TISSUE SARCOMA FOR PRECLINICAL DRUG EVALUATION